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Abstract
Background: Biodegradable stents that disintegrate after a period of time are expected to be well tolerated and
have advantages over other stents that are more commonly used in practice today. Polydioxanone is a biodegradable
polymer that is widely used during surgery with absorbable sutures.
Methods: We present cases from the first four patients to undergo a tracheal polydioxanone stent insertion.
Indications included significant non-malignant tracheal stenosis in cases where primary surgical treatment was
not possible. The stents were implanted using rigid bronchoscopy and patients received regular follow-ups as
needed. This use of biodegradable stents in adult patients was a novel, previously untested approach. The study
was approved by the Institutional Ethics Committee and was based on a project entitled; “Biodegradable stents
in the management of stenoses of large airways” (project NT 14146-3/2013).
Results: Six biodegradable stents were implanted in four patients with benign stenoses. No technical difficulties
occurred and no serious or life-threatening events were recorded. All patients reported some benefit from
treatment.
Conclusion: Polydioxanone tracheal stents can be considered when a need for temporary support is expected,
and as an alternative to other stents if the latter could compromise the patient. Owing to limited experience and
observed disadvantages, further research is needed to fully assess this treatment.
Trial registration: This work is based on project NT14146 - Biodegradable stents in the management of stenoses
of the large airways (2013–2015, MZ0/NT), registered from May 1, 2013 in The Research and Development
and Innovation Information System of the Czech Republic and in ClinicalTrials.gov, reg. no. NCT02620319,
December 2, 2015.
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Background
Stenting is an important therapeutic modality for the
maintenance of lumen patency in many tubular organs,
including the trachea. Several types of stents are cur-
rently available and can be categorized according to the
following materials: silicone or other polymer stents,
self-expandable metal stents, and hybrid polymer-metal
stents (i.e. covered self-expandable metal stents) [1, 2].
Silicone stents are inserted using rigid bronchoscopy; they
are well-tolerated, easily removable, and flexible. However,
they disturb airway mucociliary clearance and are prone
to migration. Other complications associated with silicone
stents include granuloma formation that narrows both
ends of the stent, and obstructions secondary to trapped
secretions. Self-expanding metal airway stents can be
inserted using flexible bronchoscopy and, if not covered,
affect mucociliary transportation to a lesser degree than is
observed with silicone stents. However, with uncovered
stents, the stent mesh can become overgrown with tra-
cheal epithelium, which can make removal difficult. These
stents also induce a significant mucosal inflammatory
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response. Additionally, they can fragment, extrude, and
penetrate into neighboring structures, such as the esopha-
gus or large vessels. The use of uncovered metal stents in
benign stenosis has been limited and controversial [2, 3].
The ideal airway stent has yet to be developed [1, 2, 4, 5].
Biodegradable (BD) stents are made of knitted polymer fi-
bers that degrade when placed in the body; extraction of
the device is, therefore, unnecessary. Several in vitro and in
vivo studies of tracheal BD stents composed of various ma-
terials have been conducted [5–14].
Polydioxanone is a biodegradable polymer in the poly-
ester family, which has attracted a lot of interest due to
its exquisite biocompatibility and is currently available
on the market in the form of absorbable suture material.
It is degraded by hydrolysis (of its ester bonds), which is
accelerated under low pH conditions, into harmless deg-
radation products. Polydioxanone tracheal stents appear
to be well tolerated by the tracheal mucosa, retain their
mechanical strength for as long as 6 weeks, and, in
animal models, completely degrade after approximately
15 weeks [10]. They have been successfully used in
humans as mechanical support for tracheal transplants,
during treatment of obstructive airway complications after
lung transplantation, and in children with airway stenosis
[15–18]. This work presents our preliminary experience
with the use of polydioxanone stents in adult patients suf-
fering from different types of tracheal stenosis. At the time
of this study, this particular indication for BD stents was
novel and had not been tested previously.
Methods
We present cases from the first four patients treated
with BD polydioxanone stents between September 2013
and December 2014 (including an adequate follow-up
period) at Thomayer Teaching Hospital’s Department
of Respiratory Medicine in Prague, Czech Republic.
The study was approved by the Ethics Committee of
The Institute for Clinical and Experimental Medicine
and Faculty Thomayer Hospital, June 27, 2012, ref. no.
1231/11(G11 06–26) and was based on a project enti-
tled; “Biodegradable stents in the management of sten-
oses of large airways” (project NT 14146-3/2013); the
project was awarded a special purpose grant with sup-
port from the Internal Grant Agency of the Czech Re-
public Ministry of Health.
Inclusion criteria
Indications for implantation were functionally signifi-
cant nonmalignant stenoses of the trachea where pri-
mary surgical resection was not possible. Every patient
was reviewed by at least two interventional pulmonolo-
gists and a thoracic surgeon to determine the best thera-
peutic option. Bronchoscopy and computed tomography
of the trachea were considered essential to confirm the
diagnoses. All patients signed an informed consent form
prior to undergoing the procedure. Contraindications in-
cluded the presence of aero-digestive communication and
pregnancy.
Stents and implantation technique
The procedure utilized self-expandable, biodegradable,
polydioxanone tracheal stents manufactured by ELLA-CS
Ltd. (Hradec Králové, Czech Republic). The stents had the
following dimensions (mm) (diameter x length): 18 × 50,
18 × 70, 20 × 50, and 20 × 70. The stents were knitted
from polydioxanone monofilament, had sparse mesh near
their ends and two gold radiopaque markers (Fig. 1). They
were delivered in an airtight container, which was opened
just prior to the procedure. The stents were manually
loaded into the application apparatus, which consisted of
a hollow plastic tube (sheath) and a flexible plastic piston
inside the sheath. This apparatus worked as a pull-back
delivery system, which was introduced through a rigid
bronchoscope. The trachea was intubated with a rigid
bronchoscope that was 43 cm in length and had an in-
ternal diameter of 8.5–11.0 mm (Karl Storz, Germany).
Patients were placed under total intravenous anesthesia
and jet ventilation. A flexible bronchoscope was used to
measure the distance from the desired distal end location
of the stent to the outer tube orifice. This distance was
then marked on the delivery apparatus, which was intro-
duced through a rigid tube to the desired depth of the dis-
tal end. After insertion, the position of the stent was
determined and, if necessary, repositioned using rigid for-
ceps. The final step was in-stent balloon dilation. In three
Fig. 1 A polydioxanone tracheal stent with two golden radiopaque
markers
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patients, a thoracic surgeon secured the stent in place via
external (percutaneous) fixation. In other words, one su-
ture was passed through the stent, the tracheal wall, soft
tissues, and skin; the suture was then knotted on the skin
of the neck [19]. The suture was removed 2 to 3 weeks
after implantation.
Postoperative management and follow up
After insertion, patients were admitted to either the in-
tensive care unit, or a standard ward, for at least 1 day
of hospitalization. Inhalation of nebulized salbutamol or
ipratropium was administered and intravenous methyl-
prednisolone (40–80 mg) was usually administered on
the day of the procedure. Alpha-escin (40 mg, p.o. tid)
was recommended for at least 2 weeks to alleviate con-
comitant edema. The first bronchoscopy follow up was
carried out during the first post-implantation week using
topical anesthesia. Additional follow–ups (including
bronchoscopy) were performed on a monthly or as-
needed basis.
Results
Between July 2013 and August 2014, six biodegradable
stents were implanted in four patients with nonmalig-
nant tracheal stenosis (Table 1). No technical difficul-
ties occurred during the procedures, and all patients
reported immediate relief from dyspnea. By December
2014, all stents had completely degraded. No serious or
life-threatening events were recorded.
Patient 1
A 59-year-old man had post-tracheostomy stenosis. He
had undergone a heart transplantation, which had been
followed by numerous complications requiring pro-
longed mechanical ventilation. An irregular stenosis
with two fractured tracheal cartilages was found; this
resulted in an 80 % lumen reduction and a stricture
length of 5 cm (Fig. 2). The patient was unable to
undergo further surgery without significant risk. In
March 2013, balloon dilation was performed and a
straight silicone stent was inserted. The patient suffered
from frequent exacerbations involving dyspnea caused by
mucus impaction and a persistent cough despite appropri-
ate supportive treatment. In September 2013, the Dumon
stent was replaced with a BD stent. After removal of the
silicone stent, a significant residual stenosis (lumen reduc-
tion of 50 %) was still present. The insertion of the BD
stent went smoothly and tracheal patency was excellent
(Fig. 3). However, the stent appeared to be easily movable
and given our lack of previous experience, a thoracic sur-
geon was enlisted to fix the stent externally to prevent dis-
location. The patient reported marked improvement of his
dyspnea and fewer difficulties with expectoration; no fur-
ther occurrences of intermittent worsening of dyspnea
due to mucus stagnation were observed. Follow–up bron-
choscopy revealed minor irritation of the tracheal mucosa,
hypertrophy between the stent fibers, and a small degree
of non-purulent secretion (Fig. 4). Three months after im-
plantation, the patient began to cough up small bits of fi-
bers (no longer than 15 mm) (Fig. 5). This episode lasted
approximately 10 days, and the patient described the
process as “very unpleasant”; however, his dyspnea did not
worsened. Bronchoscopy found that the lower part of the
stent, which previously had poor contact with the mucosa
due to a spacious trachea, had disappeared (Fig. 6). The
remainder of the stent, with its fibers nearly encased in
hyperplastic mucosa, had not been breached. Neither re-
stenosis, nor any other situation necessitating treatment
of any kind, occurred. Five months after implantation, the
remainder of the stent was still observed in situ. We noted
a significant reduction in inflammation and fewer secre-
tions. Seven months after implantation, no biodegradable
materials were found in patient’s trachea; however, the
cobblestone pattern that the stent mesh had left on the
mucosa was still apparent (Fig. 7). Some degree of small,
insignificant narrowing remained, but further intervention
was not needed.
Patient 2
A 52-year-old woman suffered from a complex post-
intubation stenosis. She was first referred to our depart-
ment in 2012 and a silicone stent was inserted to treat a
Table 1 Patients
Pt. Etiology of narrowing Localization in
trachea
Type Reduction of lumen
cross-section (%)
Stents










50 18 × 70 Yes 88
2 Post-intubation upper and
middle third
scar stricture 75 18 × 70 No 90
3 Tracheomalacia
associated with a. lusoria
middle and
lower third
malacia 90 20 × 70 Yes 92
20 × 70 Yes 85
4 Post–tracheotomy upper third hourglass 75 20 × 50 Yes 94
20 × 50 Yes 86
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4 cm long irregular narrowing that affected the upper
and middle portions of her trachea. Unabated alcohol in-
take, together with advanced hepatic cirrhosis, contrain-
dicated tracheal resection. With the exception of minor
expectoration difficulties, she did well with the silicone
stent until November 2013, when she presented with a
growth of granulation tissue and mucosal swelling
above the proximal end of the stent. After removal of
the stent, a significant residual stenosis persisted des-
pite laser resection of the granulation and balloon
dilation. We then inserted a BD stent, which very nicely
reopened the narrowed segment; the patient reported a
reduction in coughing and expectoration compared to
the silicone stent. Thirteen weeks after implantation,
the patient presented with dyspnea and stridor, together
with a history consistent with a respiratory infection.
We found significant narrowing caused by granulations
protruding between the holes of the stent mesh. The
stent integrity had been breached and several fibers
Fig. 3 BD stent in trachea immediately after implantation
Fig. 4 Proximal portion of the stent 3 months after implantation.
Inflammation and hyperplasia of mucosa is seen, fibers are partially
covered by the mucosa
Fig. 5 Bits of fibers coughed up by one of the patients
Fig. 2 Severe post-tracheotomy stenosis before treatment
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were projecting into the lumen. All visible stent compo-
nents were removed, followed by partial laser resection
of the granulation and balloon dilation. Ultimately, the
patient was referred for tracheostomy due to residual
narrowing that was primarily caused by edema. One
week later, the inflammation receded and the patient
was successfully decannulated. Although some insig-
nificant narrowing remained, no further interventions
were needed.
Patient 3
A 70-year-old man had severe tracheomalacia associated
with arteria lusoria. Despite having undergone surgical
treatment for the anomaly (reimplantation of the aber-
rant artery into the right common carotid artery) at a
different hospital in 2012, a nearly-complete collapse of
the lower and middle trachea persisted. As such, a
tracheostomy appeared to be the patient’s only option.
He complained of a persistent cough, stagnated secre-
tions, and recurrent aspiration of small amounts of fluid
when swallowing. A significant narrowing distal to the
end of the tracheostomy tube was observed. However,
the patient was not able to tolerate a longer tube, which
proved too difficult for him to keep clean. In May 2014,
a BD stent was implanted distal to the level of the trache-
ostomy. Since the stent reached just below the level of the
tracheostomy it was secured using external fixation, and
the tracheostomy tube was left in situ. The patient re-
ported significant relief and was able to expectorate. Some
degree of mucosal hypertrophy and minor secretion stag-
nation were observed. Thirteen weeks after implantation,
the stent was found to be partially absorbed and recurrent
narrowing was observed. Another BD stent with the same
dimensions was introduced. It, too, induced some degree
of mucosal hypertrophy and granulation growth, but the
overall effect that persisted after the second stent’s absorp-
tion was better than had been observed prior to BD stent-
ing: a more spacious lumen that was less prone to collapse
had been achieved.
Patient 4
A 59-year-old man who had previously survived a car
accident presented with a severe, hour-glass shaped,
post-tracheostomy stenosis in the upper trachea. Surgi-
cal resection was considered too risky due to the patient
having coronary artery disease, as well as his recent re-
covery from polytrauma. After balloon dilation and in-
sertion of a BD stent, the patient experienced immediate
and excellent clinical benefits. At the 1-month post-
implantation follow-up, several islands of granulation tis-
sue were observed to be growing through the stent mesh.
These led to some reduction of the tracheal lumen, but
not more than 30 %. The patient was prescribed inhaled
corticosteroids (budesonide dry powder inhaler, 400 mcg,
b.i.d.) and clarithromycin (p.o. for 3 weeks). At the next
follow up, the reduction had receded slightly and the pa-
tient remained well. On the 88th post-implantation day,
he started to cough up pieces of stent fiber and com-
plained of dyspnea. An examination found re-stenosis due
to granulations and recurrent scaring, which necessitated
balloon dilation and insertion of a new BD stent. Four
months later, the patient was in good health and no sig-
nificant tracheal narrowing was observed during absorp-
tion of the second stent.
Fig. 7 Seven months after implantation; cobblestone pattern of
mucosal hyperplasia represents imprint of degraded stent
Fig. 6 Three months post-implantation, distal part of the stent is missing
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Discussion
We inserted six BD stents into four patients with tra-
cheal narrowing. This treatment of adult patients was
novel, and there have only been a few cases in which
polydioxanone stents were used to maintain airway
patency: Lischke et al. published results from six pa-
tients with bronchial stenosis after lung transplantation
[15]; Vondrys et al. described treatment in four children
with tracheal narrowing [16]; and BD stents have re-
cently been used in children [17, 18].
Stents from biodegradable materials only provide tem-
porary support. Their use is especially indicated in cases
where time-limited support for healing is needed. Non-
malignant stenoses may stabilize over time as the tissue
stiffens. The absence of a recurrent post-intubation sten-
osis after silicone stent removal at 1 year ranges from
40 % (when the stent was in place for 6 months) to more
than 60 % (when it remained in place for 18 months)
[3]. It is worth noting that both of the above-mentioned
time periods exceed the degradation time of polydioxa-
none airway stents; however, this time can be extended
through multiple stentings, which has been shown to be
effective [15, 16]. The airway remodeling can be achieved
using BD stents; moreover, we believe the induction of
mucosal hyperplasia that often accompanies BD stenting
can contribute to stabilization of the narrowing and the
total time needed for mechanical support in the airways,
including multiple implantations of BD stents, may be
shorter.
The implantation of all BD stents went smoothly and
technical success was achieved in each case. We utilized
a rigid bronchoscope and operated under visual control.
While this method is suitable in adults with large, spa-
cious airways, fluoroscopic guidance is recommended in
the smaller airways of children [16]. In three patients we
used external fixation of the stent due to concerns over
dislocation [19]. This procedure was simple and did not
represent any additional risk to the patient. Fixation of
BD stents is recommended when we suspected that the
stent was likely to slip out of position, e.g. when there is
a tough, irregular funnel-shaped stenosis or stenosis in
the upper portion of trachea. Of course fixation only
took place when it was technically possible, i.e. at least
part of the stent was located in the extrathoracic trachea.
Longer BD stents can be used to address this particular
issue in distal tracheal stenosis. As mentioned above,
fixation is temporary, and the suture is removed 2 to
3 weeks after implantation, which is long before the start
of the degradation process and before radial strength is
compromised. Fixation simply holds the stent in place
until some of the stent fibers are encased in hyperplastic
mucosa.
All patients reported relief from their symptoms. During
the post-implantation period, patients only complained of
coughing; however, those who had previously been treated
with silicone stents reported coughs of reduced intensity
and decreased expectoration. Mild irritation of the tra-
cheal mucosa, mucosal hyperplasia, and stagnation of
non-purulent secretions were also observed in our patients.
Novotny et al. [10] described histopathologic changes
in tracheal mucosa after polydioxanone-stenting in rab-
bits. The most intensive period of inflammation was
observed 5 weeks after implantation, with the majority
of inflammation occurring during the first 3 months
after implantation. Rapid deterioration of stent integrity
began approximately 12–13 weeks (90 days) after im-
plantation. This was followed by an apparent reduction
in inflammatory changes; while some remnants of the
stent were still observed in situ 5 months after implant-
ation. Findings of a similar nature have also been re-
ported by other authors [15, 16].
We used BD stents on only four patients, two of whom
were naive to previous stenting. Issues that appeared in
patients with previously-inserted silicone stents encour-
aged us to replace them. In both cases, significant narrow-
ing persisted after removal of silicone stents; therefore, we
do not think that the previous stenting procedures sub-
stantially influenced our results.
Expectoration of stent particles is a concomitant and
predictable situation [15] that indicates the start of
rapid degradation. Given their relatively small dimen-
sions, we believe that the remnants of BD stents are
unlikely to occlude the trachea (Fig. 5); nonetheless,
this symptom should lead clinicians to perform a
follow-up bronchoscopy if restenosis (due to the char-
acter of the tracheal disease), is expected. Nevertheless,
these cases can be prevented with early re-stenting.
The onset of rapid degradation was relatively constant
(Table 1), which corresponds to previous observations
[10, 15, 16]. Serio and colleagues [18] published unsat-
isfactory experiences with polydioxanone stents that
were especially associated with a lack of radial force;
however, they were working with stents having a com-
pletely different structure. We recorded growth of exo-
phytic granulations, which led to restenosis in two
patients, however we suspect that respiratory infections
to have been the trigger of these occurrences. The
growth of granulations was a bit disappointing since we
had expected perfect biocompatibility with polydioxa-
none stents and minimal mucosal inflammatory reac-
tions. Polydioxanone fibers can induce granulations as
described by Lischke et al. and Vondrys et al. [15, 16],
but other risk factors, such as infections and gastro-
esophageal reflux, can also contribute to their develop-
ment. These conditions are sometimes difficult to
identify and when revealed, they deserve thorough
treatment. Nevertheless, clinicians need to be ready to
deal with granulations during treatment with BD stents.
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In our particular cases, they were resolved via endo-
scopic removal, balloon dilation, and re-stenting.
On the other hand, fibrosing processes and chondrifi-
cation are cornerstones for the stabilization of a stenosis.
The presence of a biodegradable stent can positively in-
fluence the buildup of cartilage [11]. We assume mucosa
hyperplasia induced by BD stents to have been an inde-
pendent factor that contributed to the augmentation of
the malatic trachea.
Conclusions
Biodegradable tracheal stents are novel types of tracheal
support devices that appear capable of treating benign
tracheal stenosis; however, their effectiveness has yet to
be verified. Having limited experience based on an ana-
lysis of four patients, we must emphasize some import-
ant challenges. Due to time-limited mechanical support
of the trachea, re-stenosis may develop during degrad-
ation of the stent. Therefore, success depends on follow-
ups by an interventional pulmonologist and good patient
compliance. BD stents are not free of side effects: i.e.,
they may induce growth of granulations and expector-
ation of stent particles, which is a specific BD stent re-
lated phenomenon; which, as would be expected, is
perceived negatively by patients. While not dangerous, it
does indicate the onset of rapid degradation of the stent
and associated effects. Repeated bronchoscopy and re-
stenting may be necessary if tracheal narrowing remains.
Despite these disadvantages, stenosis remodeling can
be achieved leaving the patient without any artificial
supportive devices in their airways. The induction of in-
flammation followed by the development of mucosal
hypertrophy may lead to difficulties, but may also result
in exploitable stabilizing effects, particularly in patients
with malacia. Based upon our limited experience, we are
unable to postulate an unequivocal statement about this
novel method, but we believe that these types of stents
may overcome the disadvantages of silicone and metal
stents. Further research in this field is needed to confirm
our hypothesis. Future modifications in stent design and
materials might further improve BD stent characteristics,
their biological compatibility, and effects.
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